Allergan Sues Imprimis, Prescriber’s Choice, Sincerus Florida

September 8, 2017: By Jon Swedien

legal issuesAllergan filed lawsuits Sept. 7 against Imprimis Pharmaceuticals, Prescriber’s Choice, and Sincerus Florida, claiming they are illegally selling unapproved new drugs.

Allergan filed one complaint against Imprimis and one against both Prescriber’s Choice and Sincerus in the US District Court for the Central District of California.

Allergan’s complaints allege that the companies are illegally manufacturing and selling unapproved new drugs under the false guise that they are engaged in lawful compounding. Allergan also claims the three are engaging in false and misleading advertising and promotion of unapproved new drugs.

In a prepared statement, Allergan said it was taking this step because companies such as Allergan have a duty to put the safety of their patients first and it believes the three defendants are putting patients and physicians at risk.

Imprimis and Sincerus are US FDA-registered 503B outsourcing facilities. Prescriber’s Choice is a management company that assist physicians.

Allergan also claims that all three defendants are in violation of the Lanham Act, which protects against trademark infringements and state laws.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Imprimis’ Q3-2017 Ophthalmic Revenues Increase 60 Percent, Total $4.9 Million

iVeena Completes Phase I/IIa Study of IVMED-10 for Post-Cataract Inflammation

RegeneRx Announces Positive Phase III Results for RGN-259 in Dry Eye

Bill Link, PhD, Joins LENSAR as Board Chairman

Apellis Prices $150 Million Initial Public Offering

Oculentis Recalls Lentis IOLs in Philippines Due to Reports of Postoperative Opacification

Valeant Reports 1 Percent Growth for Bausch + Lomb Segment in Q3-2017

Tivanisiran is Generic Name for Sylentis’ Dry Eye Candidate

Alimera’s Q3-2017 Revenues Increased 18 Percent; Company Sees Expanded Market for Iluvien

Iridex’ Revenues Increase 11 Percent in Q3-2017; 111 Cyclo G6 Systems, 7,800 G6 Probes Shipped

Glaukos’ Net Sales Increase 37 Percent in Q3-2017

Regeneron’s US Eylea Sales Increase 12 Percent in Q3-2017

Second Sight Reports Q3-2017 Net Sales of $1.6 Million, New $122,500 CMS Rate for Argus II

Tear Film Innovations, Exicure, Genisphere Complete Financing Rounds

Opternative Sues Warby Parker Over Online Eye Exams

Bausch + Lomb Receives US FDA Approval for Vyzulta for IOP Reduction in Glaucoma Patients

Allergan Plans Cost Cuts, Takes Impairment Charge as Restasis Generics Loom

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022